Stocktoria
XBiotech Inc. XBIT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-04-15
Chart by TradingView
3/9
Piotroski F — financial health
14.89
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | — | $0 | $4.0M | $18.4M |
| Gross profit | — | — | $0 | $3.4M | $12.6M |
| Operating income | -$55.7M | -$42.5M | -$37.5M | -$34.5M | -$25.1M |
| Net income | -$45.5M | -$38.5M | -$24.6M | -$32.9M | -$17.4M |
| Operating cash flow | -$39.9M | -$31.0M | -$18.7M | -$14.8M | $69.4M |
| Free cash flow | -$40.2M | -$32.3M | -$19.1M | -$15.4M | $65.9M |
| Total assets | $150.1M | $199.1M | $226.6M | $246.1M | $275.2M |
| Total liabilities | $9.7M | $16.8M | $7.8M | $5.7M | $5.8M |
| Shareholders' equity | $140.3M | $182.3M | $218.8M | $240.4M | $269.4M |
| Ratios | |||||
| Gross margin | — | — | — | 83.8% | 68.4% |
| Operating margin | — | — | — | -860.1% | -136.4% |
| Net margin | — | — | — | -820.4% | -94.7% |
| FCF margin | — | — | — | -384.3% | 358.4% |
| Return on assets | -30.3% | -19.4% | -10.8% | -13.4% | -6.3% |
| Return on equity | -32.4% | -21.1% | -11.2% | -13.7% | -6.5% |
| Current ratio | 16.01 | 11.56 | 33.07 | 54.07 | 71.49 |
| Revenue growth | — | — | -100.0% | -78.2% | -58.2% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 22,438 | $52,729 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 14.89 (safe)
- Working capital / assets 0.793
- Retained earnings / assets -0.909
- EBIT / assets -0.371
- Equity / liabilities 14.421
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001626878 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.